- Home
- ANAB vs ASTL Comparison
ANAB vs ASTL Comparison
Compare ANAB & ASTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- ASTL
- Stock Information
- Founded
- ANAB 2005
- ASTL 1902
- Country
- ANAB United States
- ASTL Canada
- Employees
- ANAB N/A
- ASTL N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- ASTL Steel/Iron Ore
- Sector
- ANAB Health Care
- ASTL Industrials
- Exchange
- ANAB Nasdaq
- ASTL Nasdaq
- Market Cap
- ANAB 621.1M
- ASTL 532.0M
- IPO Year
- ANAB 2017
- ASTL N/A
- Fundamental
- Price
- ANAB $23.17
- ASTL $6.80
- Analyst Decision
- ANAB Buy
- ASTL
- Analyst Count
- ANAB 10
- ASTL 0
- Target Price
- ANAB $44.25
- ASTL N/A
- AVG Volume (30 Days)
- ANAB 775.6K
- ASTL 1.2M
- Earning Date
- ANAB 08-04-2025
- ASTL 07-01-2025
- Dividend Yield
- ANAB N/A
- ASTL 2.94%
- EPS Growth
- ANAB N/A
- ASTL N/A
- EPS
- ANAB N/A
- ASTL N/A
- Revenue
- ANAB $111,872,000.00
- ASTL $1,635,857,227.00
- Revenue This Year
- ANAB N/A
- ASTL $0.95
- Revenue Next Year
- ANAB $24.39
- ASTL $21.63
- P/E Ratio
- ANAB N/A
- ASTL N/A
- Revenue Growth
- ANAB 387.20
- ASTL N/A
- 52 Week Low
- ANAB $12.21
- ASTL $4.17
- 52 Week High
- ANAB $41.31
- ASTL $12.14
- Technical
- Relative Strength Index (RSI)
- ANAB 56.01
- ASTL 68.23
- Support Level
- ANAB $22.46
- ASTL $5.98
- Resistance Level
- ANAB $24.17
- ASTL $6.99
- Average True Range (ATR)
- ANAB 1.72
- ASTL 0.37
- MACD
- ANAB -0.01
- ASTL 0.13
- Stochastic Oscillator
- ANAB 73.23
- ASTL 91.71
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ASTL Algoma Steel Group Inc.
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.